Company: | Paul McBarron, (908) 517-7330, pmcbarron@cyclacel.com |
Investor Relations: | Grace Kim, IR@cyclacel.com |
The Investor Relations website contains information about Cyclacel Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial ...
As a clinical-stage, biopharmaceutical company, we develop innovative cancer medicines based on cell cycle, transcriptional regulation, epigenetics and mitosis ...
People also ask
What is a Cyclacel?
What is the email format for Cyclacel Pharma?
Investor Relations: Russo Partners LLC, Robert Flamm, (212) 845-4226, robert.flamm@russopartnersllc.com. © Copyright 2014 Cyclacel Pharmaceuticals, Inc. All ...
This information can be used by investors to verify and understand the financial position of the company. Many, but not all SEC filings are available in the ...
Common Stock (CYCC) including earnings per share, earnings forecasts at Nasdaq ... Common Stock (CYCC) Earnings. Data is currently ... Investor Relations · Contact ...
Roth Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service ...